Editor’s note: This article is about a research study that looked at the effects of taking the anti-diabetes drug metformin before surgery for renal cell carcinoma (RCC). The researchers found that metformin might improve patients’ survival times. However, more research is needed to see whether metformin is truly beneficial.
“Patient exposure to metformin before undergoing nephrectomy for renal cell carcinoma (RCC) may have an effect on patient survival, according to the results of a study published recently in Urologic Oncology.
“Results of the study showed a positive effect of the anti-diabetes drug in an unadjusted analysis; however, this effect was not seen on multivariable analysis.
“ ‘Interest in metformin as a possible therapeutic option for RCC has been generated by emerging data from both observation and prospective studies assessing the association between risk of cancer-related death and exposure to metformin for a variety of malignancies,’ wrote Sarah P. Psutka, MD, of the department of urology at Mayo Clinic, Rochester, Minn., and colleagues.”